BCLI: Phase 3 Trial of NurOwn® in ALS to Initiate in 2Q17
Yahoo! Finance USA,
By David Bautz, PhD NASDAQ:BCLI Business Update Phase 3 Trial of NurOwn® in ALS to Initiate in 2Q17 On December 19, 2016…
By David Bautz, PhD NASDAQ:BCLI Business Update Phase 3 Trial of NurOwn® in ALS to Initiate in 2Q17 On December 19, 2016…
By David Bautz, PhD NASDAQ:BCLI Seeking Regulatory Approval in Canada for NurOwn® in ALS On February 21, 2017, BrainStorm Cell…
By David Bautz, PhD NASDAQ:BCLI Plan for Phase 3 Program and Hospital Exemption On December 19, 2016, BrainStorm (BCLI…
Rabinovich-Nikitin I, Ezra A, Barbiro B, Rabinovich-Toidman P, Solomon B. Chronic administration of AMD3100 increases survival…